| Ytd | -78.93% | |
| 1y | -72.02% |
| Open | 3.95 | Prev Close | 3.99 | Low | 3.77 | High | 4.06 | Mkt Cap | 322.79M |
| Vol | 7.27M | Avg Vol | 3.73M | EPS | -3.75 | P/E | N/A | Forward P/E | -4.89 |
| Beta | 1.74 | Short Ratio | 11.44 | Inst. Own | 111.47% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 8.98 | 200-d Avg | 13.17 | 1yr Est | 40.93 |
EYPT News
U.S. futures rise, but Xenon plunges 27.6% after pausing psychiatry trial enrollment over neuropsych
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company commit
Eyepoint Pharmaceuticals (NASDAQ: EYPT - Get Free Report) and Bristol Myers Squibb (NYSE: BMY - Get
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
EyePoint, Inc. (EYPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Wall Street analysts changed outlook on top companies. Check out complete rating changes, including
TD Cowen analyst Tara Bancroft downgrades EyePoint (NASDAQ:EYPT) from Buy to Hold and lowers the
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million.